Business
Posting of Annual Report & Notice of AGM
Cambridge Cognition Holdings plc has published its Annual Report and Accounts for the year ended 31 December 2025, along with the Notice of its Annual General Meeting, which will be held on 21 May 2026. These documents are available on the company's website for shareholders. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n\n24 April 2026\nCambridge Cognition Holdings plc \n(\"Cambridge Cognition\" or the \"Company\")\n \n \nPosting of Annual Report & Notice of AGM\n \n \nCambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, confirms that the Annual Report and Accounts for the year ended 31 December 2025 (\"2025 Annual Report\") and the Notice of the Annual General Meeting (\"AGM\") have been published on the Company's website. Hard copies have been posted to those shareholders who requested them.\n \nThe AGM is to be held at 9 am BST on 21 May 2026 at the registered office of the Company, Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU. \n \nA copy of the 2025 Annual Report and other documents are available on the Company's website: https://cambridgecognition.com/reports-and-accounts/\n \n \n \n \nEnquiries:\n \n\n\n\n\nCambridge Cognition Holdings plc \nRob Baker, Chief Executive Officer\nRonald Openshaw, Chief Financial Officer\n \n\n\nTel: 01223 810700 \[email protected] \n\n\n\n\nCavendish Capital Markets Limited (NOMAD and Joint Broker)\nGeoff Nash / Elysia Bough / Joe Smith\nHarriet Ward\nNigel Birks\n \n\n\nTel: 020 7220 0500\nCorporate Finance\nCorporate Broking\nLS Specialist Sales\n\n\n\n\n \nSinger Capital Markets Limited (Joint Broker) \nAmber Higgs / James Serjeant / Daniel Ingram\n\n\n \nTel: 020 7496 3000\n \n\n\n\n\n \nNotes to Editors\n \nAbout Cambridge Cognition\n \nCambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.\n \nBuilt on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:\n \n· Clinical Studies for new pharmaceuticals;\n· &...